Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
about
Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patientsDose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allEffect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group studyCYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropionPharmacogenetics as a tool to tailor antiretroviral therapy: A reviewPerspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbiditiesPharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsIndividualization of antiretroviral therapy--pharmacogenomic aspectInsights into CYP2B6-mediated drug-drug interactionsEffect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV InfectionAfrican genetic diversity: implications for human demographic history, modern human origins, and complex disease mappingDurability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.Efavirenz in the therapy of HIV infection.Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adultsFunctional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.Pharmacogenomics of antimicrobial agents.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successGenome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.PharmGKB summary: Efavirenz pathway, pharmacokineticsExploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in MalawiansPharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.The Patient Cohort of the German Competence Network for HIV/AIDS (KompNet): a profile.Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descentWorldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsIndividualization of antiretroviral therapy.Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
P2860
Q21245026-20AE1F6D-09C4-4F1E-A2B8-8ADD1A34B4F1Q24609011-4C8814F3-0C84-477F-91C6-E6FF3DF19B32Q24633579-68882B40-0767-45DB-B122-E77360FB8254Q24634660-983F2033-B9C1-4D9E-A74D-43FE51033FBFQ26797938-E6637AC8-9D8F-4295-BDEF-7EB68D6BB51DQ26853274-E5CD8E38-B782-434C-B207-80B86CDED565Q28069383-5D0E0E82-C4C9-41B3-AF7F-5D9E3DADCE04Q28070574-2C5C7001-D2CB-4ABC-86B4-9764405AFB31Q28078857-6AD67A36-D02C-4E9E-9FF2-A61CEE5757B4Q28548638-B027D482-4CF7-4B69-BC27-623488DE2CF4Q28748891-17784D08-05FE-42AB-AA63-544CA6C8D673Q33375532-DF6EC4B6-2CF8-4023-BF57-9D576A6C94ECQ33394593-F4E14F10-9A43-4D7A-B4F7-E458A00AE1DFQ33607011-ED010CB4-B030-45D3-932F-64D3D4DD9842Q33809438-9BF964C3-626D-41DC-BFBC-B27205DE533BQ33909980-07A66B33-2A3C-4819-B447-C88CB0B3B301Q33909996-FE593A97-1AD3-447F-AB49-CB2226BABE75Q33914723-B8F02962-E49F-4DA6-A843-619FF0FDA9F3Q34057466-96168B3B-CFFB-4B93-B38D-76C847528C2CQ34060396-78700D8C-D00C-4257-99E7-FC316D77CBA0Q34149022-B1D4A5DC-6F3F-4B40-AA20-07DF92A19772Q34495636-C83A3148-2819-4465-B607-F2D474578928Q34566233-7EFC5626-267C-44FF-AC65-7FDB42292724Q34975110-7336816D-B838-4267-88A8-585A43BFF984Q34977413-0AC57B6F-0614-499E-8F8E-64C45E60A361Q35043700-B169A300-97C2-43D2-AFD4-568FA7E63AFDQ35288691-BF66768A-DE75-4FF3-99B0-0EF8B5FDBC0EQ35426496-29B47608-062D-48FC-A54C-2695DCCC5F4CQ35518558-C075194E-3145-461F-B8AF-342C04A9785DQ35706069-63B1B71D-7752-4BCA-A418-4FB0902A6755Q35796733-892AD051-D18F-4FAD-AB6F-7E572A36BDBFQ35846143-2541FE8F-451F-4CFC-A8D5-FA5E66E6606BQ35910664-AF8FCE93-6196-4D7B-9839-B1C4C052E1BAQ35959785-3F9D35BF-2D02-4D34-9BBC-048C8007C94BQ36070182-0F259596-00D6-49A3-B013-CCD519D3F7EDQ36079108-D2F751B6-32FC-44B2-9210-2EF2961F7A28Q36087985-1DCE5A38-5439-40B7-91DD-C36B82F2F473Q36437792-A41419A8-0BC9-4B01-B65D-1743EA059E8EQ36441423-E351D381-05CF-495B-81B4-054ED517B6C0Q36554279-E6367912-34BA-46F1-AA86-A24AD3873E90
P2860
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Impact of CYP2B6 983T>C polymo ...... tions in HIV-infected patients
@ast
Impact of CYP2B6 983T>C polymo ...... tions in HIV-infected patients
@en
type
label
Impact of CYP2B6 983T>C polymo ...... tions in HIV-infected patients
@ast
Impact of CYP2B6 983T>C polymo ...... tions in HIV-infected patients
@en
prefLabel
Impact of CYP2B6 983T>C polymo ...... tions in HIV-infected patients
@ast
Impact of CYP2B6 983T>C polymo ...... tions in HIV-infected patients
@en
P2093
P2860
P50
P356
P1476
Impact of CYP2B6 983T>C polymo ...... tions in HIV-infected patients
@en
P2093
Alexander Jetter
Christian Hoffmann
Christiane Groneuer
Christoph Wyen
David J Back
Deirdre Egan
German Competence Network for HIV/AIDS
Hans Jaeger
Heidy Hendra
Heribert Knechten
P2860
P304
P356
10.1093/JAC/DKN029
P407
P577
2008-02-14T00:00:00Z